Last reviewed · How we verify
VER-01
VER-01 is a small molecule that targets the SGLT2 receptor.
VER-01 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | VER-01 |
|---|---|
| Also known as | trans-Δ9-Tetra-hydrocannabinol (THC) |
| Sponsor | Vertanical GmbH |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, VER-01 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- Efficacy and Safety of VER-01 in the Treatment of Patients With Radicular Chronic Low Back Pain (PHASE3)
- Dose-Response Characterization of VER-01 in the Treatment of Patients With Chronic Non-specific Low Back Pain (PHASE2)
- Comparison of VER-01 to Opioids in Patients With Chronic Non-specific Low Back Pain (PHASE3)
- Efficacy and Safety of VER-01 in the Treatment of Patients With Chronic Non-specific Low Back Pain (PHASE3)
- Food Effect Study of VER-01 in Healthy Volunteers (PHASE1)
- Single and Multiple Dose Study of VER-01 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VER-01 CI brief — competitive landscape report
- VER-01 updates RSS · CI watch RSS
- Vertanical GmbH portfolio CI